Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 4/20 | 0.38 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | ODC1 | P11926 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181191 | 0.82 | ODC1 (0.37) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL30156940 | 0.82 | ODC1 (0.37) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL157457 | 0.82 | ODC1 (0.37) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL27989280 | 0.82 | ODC1 (0.37) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| Water SCHEMBL21225404 | 0.81 | ODC1 (0.36) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL21225312 | 0.81 | BLM (0.39) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL180302 | 0.76 | ODC1 (0.42) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL180301 | 0.76 | ODC1 (0.42) | ARG1ARG2ODC1CYP2D6NFKB1 | |
| SCHEMBL5716372 | 0.74 | GGT1 (0.34) | ARG1ARG2THRBKMT2AMEN1 | |
| SCHEMBL9595205 | 0.74 | ODC1 (0.41) | ARG1ARG2ODC1CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050123932-A1 | Nucleic acid-chelating agent conjugates | KIRKEGAARD & PERRY LABORATORIES, INC. | 2005-06-09 | — | — | US | claimed |
| US-RE50618-E1 | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | PHARMAIN CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20200254100-A1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| US-10624966-B2 | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | PHARMAIN CORPORATION (US) | 2020-04-21 | — | — | US | disclosed |
| EP-2475358-B1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN CORP (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20180280516-A1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010613-B2 | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | PHARMAIN CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20120190097-A1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION | 2012-07-26 | — | — | US | disclosed |
| EP-2475358-A1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | Pharmain Corporation (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-1461619-B1 | IMPROVED STRUCTURED-FUNCTIONAL BONDING MATRICES FOR BIOMOLECULES | FRAUNHOFER GES FORSCHUNG (DE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2011031771-A1 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031284-A1 | POLYMERIC CARRIER COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100069293-A1 | POLYMERIC CARRIER COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2010-03-18 | — | — | US | disclosed |
| US-7368295-B2 | Nanoparticles comprising biologically active TNF which is immobilized on the same | FRAUNHOFER-GESELLSCHAFT ZUR FODERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7202472-B2 | Mass spectrometric analysis using nanoparticles | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2007-04-10 | — | — | US | disclosed |
| US-20050123932-A1 | Nucleic acid-chelating agent conjugates | KIRKEGAARD & PERRY LABORATORIES, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050048570-A1 | Structured-functional bonding matrices for biomolecules | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN | 2005-03-03 | — | — | US | disclosed |
| US-20050037516-A1 | Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to diagnose infection, cell proliferative and spongiform encephalopathic disorders | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040265392-A1 | Nanoparticles comprising biologically active tnf which is immobilized on the same | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123932-A1 | Nucleic acid-chelating agent conjugates | RNGTT, SAMHD1, DNTT | ARG1 1875/4885ARG2 2699/4885ODC1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.